Target intelligence / Profile preview

Middle molecular weight uremic toxin

Molecular classification
Other
01

Overview

Middle molecular weight uremic toxins are a heterogeneous class of solutes defined primarily by their molecular weight, typically ranging from 500 Da to 58,000 Da (0.5–58 kDa)[1][2]. This group is subdivided into small-middle (0.5–15 kDa), medium-middle (15–25 kDa), and large-middle (25–58 kDa) solutes. These toxins are clinically significant because their accumulation in kidney failure is associated with inflammation, cardiovascular disease, immunosuppression, and other complications. Notable examples include β2-microglobulin. The class does not refer to a discrete molecular entity or a single receptor, and thus is not conventionally considered a drug target. Instead, clinical intervention focuses on optimizing dialysis modalities that enhance their removal[1][2]. In summary, "Mid-molecular weight toxins" does not refer to a single molecule or receptor and is not a therapeutic target in the conventional sense. It is a functional class relevant to renal failure and dialysis, encompassing a wide spectrum of biologically diverse toxins[1][2].

Other names
middle molecular weight toxinmiddle molecule toxinmid-molecular toxinMM toxinmiddle molecule
02

Biological functions

Other
03

Disease associations

InfectionCardiovascular diseaseChronic inflammationOther
04

Safety considerations

Retention in renal failure leading to various complications (e.g., dialysis-related amyloidosis, chronic inflammation, immunodeficiency, cardiovascular risk)Difficulty in removal by standard dialysis membranes

Beyond the preview

Go deeper on Middle molecular weight uremic toxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Middle molecular weight uremic toxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call